Edgar Engleman

Edgar Engleman is a declared insider at 3 companies; the most frequent names are Bolt Biotherapeutics, Inc., Soleno Therapeutics Inc and REGENXBIO Inc. Over a trading history stretching from 12 August 2015 to 30 November 2023, the count stands at 48 filings.

Both buying and selling appear: 8 purchases worth €6.3M, against 14 sales worth €164k. The amount is not disclosed for 2 filings. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 8 share grants. So far in 2023, the count stands at no purchases and 12 sales.

A typical purchase (the median) is worth €834k. Of 6 purchases, 6 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The record was last updated on 1 December 2023 with an open-market sale (€85k) in Bolt Biotherapeutics, Inc. The last insider purchase was made public on 9 February 2021, 2,099 days ago. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.